proxyvotesnow.com
22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › SCPHARMACEUTICALS INC. › 2024-2025

SCPHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

At SCPHARMACEUTICALS INC.'s shareholder meeting held June 3, 2025, in the 2024-2025 proxy season, 92 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 544 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED… — FOR was 99.1% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SCPHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2025.

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and SCPHARMACEUTICALS INC.’s Form 8-K, filed June 9, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.

  • 5Ballot items
  • 92Asset managers
  • 544Fund votes
  • June 3, 2025Meeting date

Results at a glance

Meeting of June 3, 2025: 5 items on SCPHARMACEUTICALS INC.’s Form 8-K, filed June 9, 2025: 5 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025

Explore SCPHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by SCPHARMACEUTICALS INC.

These tallies are SCPHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SCPHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 3, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: William T. Abraham, M.D. 23,663,867---- 4,580,8046,911,852 84%Not verified—
Elect Director: Mette Kirstine Agger 23,083,224---- 5,161,4476,911,852 82%Not verified—
Elect Director: Minnie Baylor-Henry 27,995,209---- 249,4626,911,852 99.1%Not verified—
2. Ratification of the appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 35,050,98989,54815,986 --0 99.7%Not verified—
3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers 27,995,161238,93810,572 --6,911,852 99.1%Not verified—

Source: SCPHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 9, 2025 — read the filing on EDGAR.

How asset managers voted at the SCPHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 92 asset managers that disclosed a SCPHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Mette Kirstine Agger

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD
FOR: 23,083,224WITHHELD: 5,161,447
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Election of Class II Directors: Mette Kirstine Agger

SCPHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mette Kirstine Agger”): 23,083,224 for, 5,161,447 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 1,316,352 for, 1,136,340 withheld, 2,965 abstained.

FORWITHHOLD
FOR: 1,316,352ABSTAIN: 2,965WITHHOLD: 1,136,340
Largest asset managers voting on “Election of Class II Directors: Mette Kirstine Agger” at SCPHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Thrivent00 01,019,075Withhold
Vanguard915,2700 00For
Charles Schwab102,8540 00For
BlackRock80,4670 00For
CLEARWATER INVESTMENT TRUST76,8580 00For
QUANTITATIVE MASTER SERIES LLC67,1370 00For
Lincoln Financial00 028,800Withhold
Northern Trust00 024,932Withhold
Equitable7,9590 015,210Mixed
Global X22,8180 00For
Goldman Sachs00 022,276Withhold
Fidelity14,2410 00For
Pacific Life9,4780 00For
Bridge Builder Trust7,5090 00For
ProShares00 06,812Withhold
DWS00 05,901Withhold
Columbia Threadneedle5,1340 00For
Nationwide4,5250 00For
AIG/SunAmerica00 04,340Withhold
Victory Capital00 03,288Withhold
John Hancock00 2,9650Abstain
Calvert00 02,385Withhold
State Street00 01,332Withhold
PENN SERIES FUNDS INC00 01,100Withhold
Innovator ETFs Trust1,0090 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

2. Elect Director: Minnie Baylor-Henry

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 27,995,209WITHHELD: 249,462
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Election of Class II Directors: Minnie Baylor-Henry

SCPHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Minnie Baylor-Henry”): 27,995,209 for, 249,462 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,453,272 for, 2,385 withheld.

FOR
FOR: 2,453,272WITHHOLD: 2,385
Largest asset managers voting on “Election of Class II Directors: Minnie Baylor-Henry” at SCPHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Thrivent1,019,0750 00For
Vanguard915,2700 00For
Charles Schwab102,8540 00For
BlackRock80,4670 00For
CLEARWATER INVESTMENT TRUST76,8580 00For
QUANTITATIVE MASTER SERIES LLC67,1370 00For
Lincoln Financial28,8000 00For
Northern Trust24,9320 00For
Equitable23,1690 00For
Global X22,8180 00For
Goldman Sachs22,2760 00For
Fidelity14,2410 00For
Pacific Life9,4780 00For
Bridge Builder Trust7,5090 00For
ProShares6,8120 00For
DWS5,9010 00For
Columbia Threadneedle5,1340 00For
Nationwide4,5250 00For
AIG/SunAmerica4,3400 00For
Victory Capital3,2880 00For
John Hancock2,9650 00For
Calvert00 02,385Withhold
State Street1,3320 00For
PENN SERIES FUNDS INC1,1000 00For
Innovator ETFs Trust1,0090 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

3. Elect Director: William T. Abraham, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD
FOR: 23,663,867WITHHELD: 4,580,804
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Election of Class II Directors: William T. Abraham, M.D.

SCPHARMACEUTICALS INC.’s own tally for this item (“Elect Director: William T. Abraham, M.D.”): 23,663,867 for, 4,580,804 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 1,373,046 for, 1,079,646 withheld, 2,965 abstained.

FORWITHHOLD
FOR: 1,373,046ABSTAIN: 2,965WITHHOLD: 1,079,646
Largest asset managers voting on “Election of Class II Directors: William T. Abraham, M.D.” at SCPHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Thrivent00 01,019,075Withhold
Vanguard915,2700 00For
Charles Schwab102,8540 00For
BlackRock80,4670 00For
CLEARWATER INVESTMENT TRUST76,8580 00For
QUANTITATIVE MASTER SERIES LLC67,1370 00For
Lincoln Financial28,8000 00For
Northern Trust24,9320 00For
Equitable7,9590 015,210Mixed
Global X22,8180 00For
Goldman Sachs00 022,276Withhold
Fidelity14,2410 00For
Pacific Life9,4780 00For
Bridge Builder Trust7,5090 00For
ProShares00 06,812Withhold
DWS00 05,901Withhold
Columbia Threadneedle5,1340 00For
Nationwide4,5250 00For
AIG/SunAmerica00 04,340Withhold
Victory Capital00 03,288Withhold
John Hancock00 2,9650Abstain
Calvert00 02,385Withhold
State Street1,3320 00For
PENN SERIES FUNDS INC1,1000 00For
Innovator ETFs Trust1,0090 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

4. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers

Outcome not verifiedFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 27,995,161AGAINST: 238,938
Details: description as filed, official tally, votes by 92 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SCPHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 27,995,161 for, 238,938 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 31 asset managers voting on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at SCPHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Thrivent1,019,0750 00For
Vanguard915,2700 00For
Charles Schwab102,8540 00For
BlackRock80,4670 00For
CLEARWATER INVESTMENT TRUST76,8580 00For
QUANTITATIVE MASTER SERIES LLC67,1370 00For
Lincoln Financial28,8000 00For
Northern Trust24,9320 00For
Equitable23,1690 00For
Global X22,8180 00For
Goldman Sachs22,2760 00For
Fidelity14,2410 00For
Pacific Life9,4780 00For
Bridge Builder Trust7,5090 00For
ProShares6,8120 00For
DWS5,9010 00For
Columbia Threadneedle5,1340 00For
Nationwide4,5250 00For
AIG/SunAmerica4,3400 00For
Victory Capital3,2880 00For
John Hancock2,9650 00For
Calvert2,3850 00For
State Street1,3320 00For
PENN SERIES FUNDS INC1,1000 00For
Innovator ETFs Trust1,0090 00For

Fund voting reports, all 31 managers: 2,455,657 for. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 72 asset managers voting on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at SCPHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ORBIMED ADVISORS LLC3,482,9960 00For
Rubric Capital Management LP3,137,0880 00For
KING LUTHER CAPITAL MANAGEMENT CORP2,767,6830 00For
5AM Venture Management, LLC1,200,6470 00For
RICE HALL JAMES & ASSOCIATES, LLC1,136,3410 00For
Thrivent1,036,7160 00For
KINGDON CAPITAL MANAGEMENT, L.L.C.1,000,0000 00For
Nantahala Capital Management, LLC995,4380 00For
J. Goldman & Co LP586,2330 00For
APIS CAPITAL ADVISORS, LLC540,8380 00For
State Street432,3420 00For
BlackRock412,3080 00For
Stonepine Capital Management, LLC347,6870 00For
Northern Trust151,5830 00For
Charles Schwab105,6200 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC90,8070 00For
Johnson Financial Group, LLC85,1840 00For
MELLON INVESTMENTS Corp59,0450 00For
Vanguard58,5950 00For
Mitsubishi UFJ Asset Management Co., Ltd.23,0530 00For
JPMorgan18,6300 00For
Focus Partners Wealth16,2090 00For
GEODE CAPITAL MANAGEMENT, LLC15,3110 00For
AllianceBernstein15,2100 00For
Invesco14,0220 00For

Institutional-manager reports, all 72 managers: 17,844,254 for, 5,015 against. Showing the 25 largest; every one is in the interactive database (link above).

5. Ratification of the appointment of RSM US LLP as the Company's independent registered public accounting firm for the…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 35,050,989AGAINST: 89,548
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF RSM US LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

SCPHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 35,050,989 for, 89,548 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,455,657 for.

FOR
FOR: 2,455,657
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF RSM US LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YE” at SCPHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Thrivent1,019,0750 00For
Vanguard915,2700 00For
Charles Schwab102,8540 00For
BlackRock80,4670 00For
CLEARWATER INVESTMENT TRUST76,8580 00For
QUANTITATIVE MASTER SERIES LLC67,1370 00For
Lincoln Financial28,8000 00For
Northern Trust24,9320 00For
Equitable23,1690 00For
Global X22,8180 00For
Goldman Sachs22,2760 00For
Fidelity14,2410 00For
Pacific Life9,4780 00For
Bridge Builder Trust7,5090 00For
ProShares6,8120 00For
DWS5,9010 00For
Columbia Threadneedle5,1340 00For
Nationwide4,5250 00For
AIG/SunAmerica4,3400 00For
Victory Capital3,2880 00For
John Hancock2,9650 00For
Calvert2,3850 00For
State Street1,3320 00For
PENN SERIES FUNDS INC1,1000 00For
Innovator ETFs Trust1,0090 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

Largest SCPHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 36,054,409 shares outstanding at the time of that meeting.

Fund voting reports: top SCPHARMACEUTICALS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED…”, 2024-2025
#Asset manager % of shares outstanding
1Thrivent 2.83%
2Vanguard 2.54%
3Charles Schwab 0.29%
4BlackRock 0.22%
5CLEARWATER INVESTMENT TRUST 0.21%
6QUANTITATIVE MASTER SERIES LLC 0.19%
7Lincoln Financial 0.08%
8Northern Trust 0.07%
9Equitable 0.06%
10Global X 0.06%
Institutional-manager reports: top SCPHARMACEUTICALS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY'S NAMED…”, 2024-2025
#Asset manager % of shares outstanding
1ORBIMED ADVISORS LLC 9.66%
2Rubric Capital Management LP 8.70%
3KING LUTHER CAPITAL MANAGEMENT CORP 7.68%
45AM Venture Management, LLC 3.33%
5RICE HALL JAMES & ASSOCIATES, LLC 3.15%
6Thrivent 2.88%
7KINGDON CAPITAL MANAGEMENT, L.L.C. 2.77%
8Nantahala Capital Management, LLC 2.76%
9J. Goldman & Co LP 1.63%
10APIS CAPITAL ADVISORS, LLC 1.50%

Reported SCPHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

SCPHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder % outstanding Disclosure
Glazer Capital, LLC 6.86% 13G
BlackRock 6.54% 13F
Luther King Capital Management Corporation 5.90% 13G
Vanguard Group 5.53% 13F
Morgan Stanley 5.23% 13F
Geode Capital 2.24% 13F
State Street 2.04% 13F
Northern Trust 0.88% 13F
Goldman Sachs 0.34% 13F
Charles Schwab 0.29% 13F

Percentages above are of 36,054,409 shares outstanding, as reported by SCPHARMACEUTICALS INC. on its Form 10-Q dated May 13, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SCPHARMACEUTICALS INC.’s 10-Q dated May 13, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.

SCPHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).

Cite this page

proxyvotesnow.com, “SCPHARMACEUTICALS INC. 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/scpharmaceuticals-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.